TNFA (TNF Pharmaceuticals, Inc.) Utang jangka cendhak marang modal

TNF Pharmaceuticals (TNFA) focuses on developing oral TNF inhibitors, advancing the drug MYMD-1 to combat age-related decline and autoimmune dysfunction. The business is currently revising its R&D plans, adapting anti-inflammatory developments to meet the needs of gerontology. Despite fierce patent battles, the company relies on a unique method of protein targeting. This chart shows the market price is fixed at 0.00.

To protect capital amid volatility, it is crucial for investors to monitor the ratio of liabilities maturing within one year to equity, which allows for an assessment of current liquidity and credit risk; analyzing changes in short-term debt relative to equity helps determine the extent to which TNF Pharmaceuticals (TNFA) strategic alliances with biotech laboratories are funded via short-term loans, thereby impacting the company's investment attractiveness.